Case Report

Typically active ocular toxoplasmosis: a case report

Priscilla Dwianggita

Priscilla Dwianggita
Medical Doctor, Faculty of Medicine, Universitas Udayana, Bali, Indonesia. Email: tanpriscilla18@gmail.com
Online First: December 01, 2020 | Cite this Article
Dwianggita, P. 2020. Typically active ocular toxoplasmosis: a case report. Intisari Sains Medis 11(3): 798-802. DOI:10.15562/ism.v11i3.816


Background: Ocular toxoplasmosis, a potentially blinding and non-curable disease with a progressive and relapsing course, is the most common cause of infectious posterior uveitis. Infection may be congenital or acquired through ingestion of uncooked meat, contaminated vegetables, or water of different parasite Toxoplasma gondii.

Case Presentation: We report a case of a 58-year-old female who came with blurred vision and floaters in her left eye for a month. She had contact with cats, birds, and dogs, as well as eaten raw food before. On examination, anterior segments were normal with visual acuity of 6/6 in the right eye and 6/9 in the left eye. Fundus examination revealed a vitreous haze with a yellow-white exudate located between pupil and macula. Since the disease's progress may lead to recurrence and potential blindness, it must be recognized clinically, and treatment should be started as early as possible, especially in the active period. Our patient was treated with oral trimethoprim (160 mg)/sulfamethoxazole (800 mg) twice daily and topical eye drops of prednisone four times daily on the left eye. These drugs were prescribed instead of sulfadiazine/pyrimethamine, which is classical and standard therapy. After 4 weeks, the fundus examination showed the toxoplasmic lesion was significantly decreased in size, and vitreous haze was improved.

Conclusion: Trimethoprim-Sulfamethoxazole regiments as the alternative option for active ocular toxoplasmosis also shows significant improvement with less adverse effect.

References

Kijlstra A, Petersen E. Epidemiology, Pathophysiology, and the Future of Ocular Toxoplasmosis. Ocular Immunology and Inflammation. 2014;22(2):138-147.

Maenz M, Schlüter D, Liesenfeld O, Schares G, Gross U, Pleyer U. Ocular toxoplasmosis past, present and new aspects of an old disease. Prog Retin Eye Res. 2014;39:77-106.

Ozgonul C, Besirli C, G: Recent Developments in the Diagnosis and Treatment of Ocular Toxoplasmosis. Ophthalmic Res. 2017;57:1-12.

Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000;30(12-13):1217-1258.

Silveira C, Vallochi AL, Rodrigues da Silva U, et al. Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br J Ophthalmol. 2011;95(3):396-400.

Pavesio CE, Lightman S. Toxoplasma gondii and ocular toxoplasmosis: pathogenesis. British Journal of Ophthalmology. 1996;80:1099-1107.

Delair E, Latkany P, Noble AG, Rabiah P, McLeod R, Brézin A. Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19(2):91-102.

Goldenberg D, Goldstein M, Loewenstein A, Habot-Wilner Z. Vitreal, retinal, and choroidal findings in active and scarred toxoplasmosis lesions: a prospective study by spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2013;251(8):2037-2045.

Freitas-Neto CA, Cao JH, Oréfice JL, et al. Increased Submacular Choroidal Thickness in Active, Isolated, Extramacular Toxoplasmosis. Ophthalmology. 2016;123(1):222-4.

Lune AA, Pujari SN, Lune SA. Ocular toxoplasmosis: A case report with review of literature. Med J DY Patil Univ. 2014;7:818-21.

Nida Sen H, et al. Basic and Clinical Science Course Section 9: Uveitis and Intraocular Inflammation. San Fransisco: American Academy of Ophthalmology; 2019. Chapter 11, Infectious Uveitis: Nonbacterial Causes; p.207-317.

Soheilian M, Heidari K, Yazdani S, Shahsavari M, Ahmadieh H, Dehghan M. Patterns of uveitis in a tertiary eye care center in Iran. Ocul Immunol Inflamm. 2004;12(4):297-310.

Ghavidel LA, Milani AE, Bagheri M. Comparison of Azithromycin and Pyrimethamine/ Sulfadiazine Treatment in Ocular Toxoplasmosis in North West of Iran. Crescent Journal of Medical and Biological Sciences. 2017;4(2):80–84.

Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118(1):134-141.

Butler NJ, Furtado JM, Winthrop, KL, Smith JR. Ocular toxoplasmosis II: clinical features, pathology and management. Clinical & Experimental Ophthalmology. 2014;41:95-108.

Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109(5):869-878.


No Supplementary Material available for this article.
Article Views      : 27
PDF Downloads : 14